Many investors view the healthcare sector as a safe haven when the stock market is turbulent. Here are three no-brainer ...

AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...

Potential risks associated with clinical trial outcomes and regulatory approvals for pipeline products. AbbVie’s ability to offset Humira’s decline remains a critical concern. While Skyrizi ...

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

REITs pay dividends out of their funds from operations (FFO), and Vici's FFO per share is $2.61 over the last 12 months. This ...

US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AbbVie Option Activity Analysis: Last 30 Days AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi ... added several new products and drugs in aesthetics ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

The number of hedge funds tracked by Insider Monkey owning stakes in AbbVie Inc. (NYSE:ABBV) grew to 84 in Q4 2024, from 68 ...